ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

FDA, NIH Streamline Approvals For Gene Therapy Studies

June 16, 1995

In Brief: NIH Study Finds Intramural Program Tenures Few Minorities, Calls For Improvements

March 11, 1994

Leukemia Society Program In Transitional Research.

January 14, 2000

Pacific Yew Act Would Result In Duplications, Delays In Taxol Production, Witnesses Say

March 13, 1992

NCI Programs: Researchers Take “Director’s Challenge” to Develop Molecular Profiles of Tumors

December 10, 1999

NTP Board Approves Concept Of Human Cell Assay For Genetic Toxicity

March 25, 1983